An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA...

Full description

Bibliographic Details
Main Authors: Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Breast Cancer Research
Subjects:
PARP inhibitors
DNA repair
Synthetic lethality
Targeted therapy
Triple-negative breast cancer
Online Access:https://doi.org/10.1186/s13058-021-01408-9

Internet

https://doi.org/10.1186/s13058-021-01408-9

Similar Items